Fiala Ondrej, Hosek Petr, Pesek Milos, Finek Jindrich, Racek Jaroslav, Stehlik Pavel, Sorejs Ondrej, Minarik Marek, Benesova Lucie, Celer Adam, Nemcova Ivana, Kucera Radek, Topolcan Ondrej
Department of Oncology and Radiotherapeutics, Medical School and Teaching Hospital in Pilsen, Charles University, Pilsen, Czech Republic
Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic.
Anticancer Res. 2017 Nov;37(11):6469-6476. doi: 10.21873/anticanres.12102.
Erlotinib is a tyrosine kinase inhibitor targeting epidermal growth factor receptor (EGFR); it is used in the treatment of advanced non-small cell lung cancer (NSCLC). We focused on the role of serum concentration of erlotinib and its association with outcome and toxicity in patients with advanced NSCLC harbouring the wild-type EGFR gene or squamous histology.
Clinical data of 122 patients were analyzed. Serum samples were collected within four weeks after the initiation of treatment.
There was no significant association of erlotinib concentration with PFS nor OS (p=0.352 and p=0.6393). Significant associations of erlotinib concentration with grade of skin rash and diarrhoea (p<0.0001 and p<0.0001) were found. Skin rash and diarrhoea were significantly associated with PFS (p=0.0338 and p=0.0001) and OS (p=0.0064 and p=0.0353).
Erlotinib concentration was not associated with outcome. Erlotinib concentration was associated with occurrence and severity of skin rash and diarrhoea; the outcome was associated with erlotinib toxicity.
厄洛替尼是一种靶向表皮生长因子受体（EGFR）的酪氨酸激酶抑制剂；用于治疗晚期非小细胞肺癌（NSCLC）。我们重点研究了野生型EGFR基因或鳞状组织学的晚期NSCLC患者血清中厄洛替尼浓度的作用及其与疗效和毒性的关系。
分析了122例患者的临床资料。在开始治疗后四周内采集血清样本。
厄洛替尼浓度与无进展生存期（PFS）和总生存期（OS）均无显著相关性（p = 0.352和p = 0.6393）。发现厄洛替尼浓度与皮疹和腹泻的分级有显著相关性（p < 0.0001和p < 0.0001）。皮疹和腹泻与PFS（p = 0.0338和p = 0.0001）和OS（p = 0.0064和p = 0.0353）显著相关。
厄洛替尼浓度与疗效无关。厄洛替尼浓度与皮疹和腹泻的发生及严重程度相关；疗效与厄洛替尼毒性相关。
